UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/611,934	07/03/2003	Sadao Kanbe	45360	3959
/	7590 09/25/200 ABRAMS, BERDO &	EXAMINER		
1300 19TH STREET, N.W.			HAIDER, SAIRA BANO	
SUITE 600 WASHINGTOI	N,, DC 20036		ART UNIT	PAPER NUMBER
			1796	
			MAIL DATE	DELIVERY MODE
			09/25/2008	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Advisory Action Before the Filing of an Appeal Brief

Application No.	Applicant(s)	
10/611,934	KANBE ET AL.	
Examiner	Art Unit	
SAIRA HAIDER	1796	

	SAIRA HAIDER	1796	
The MAILING DATE of this communication appe	ars on the cover sheet with the c	orrespondence add	ess
THE REPLY FILED <u>08 September 2008</u> FAILS TO PLACE THIS	S APPLICATION IN CONDITION F	OR ALLOWANCE.	
1. The reply was filed after a final rejection, but prior to or on application, applicant must timely file one of the following application in condition for allowance; (2) a Notice of Appetor Continued Examination (RCE) in compliance with 37 C periods:	replies: (1) an amendment, affidavit eal (with appeal fee) in compliance	, or other evidence, w with 37 CFR 41.31; or	hich places the (3) a Request
a) The period for reply expires <u>3</u> months from the mailing date	of the final rejection.		
b) The period for reply expires on: (1) the mailing date of this An no event, however, will the statutory period for reply expire la Examiner Note: If box 1 is checked, check either box (a) or (I MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f	iter than SIX MONTHS from the mailing b). ONLY CHECK BOX (b) WHEN THE).	date of the final rejectio	n. .ED WITHIN TWO
Extensions of time may be obtained under 37 CFR 1.136(a). The date of have been filed is the date for purposes of determining the period of extunder 37 CFR 1.17(a) is calculated from: (1) the expiration date of the set forth in (b) above, if checked. Any reply received by the Office later may reduce any earned patent term adjustment. See 37 CFR 1.704(b). NOTICE OF APPEAL	ension and the corresponding amount of hortened statutory period for reply origin	of the fee. The appropria nally set in the final Office	te extension fee e action; or (2) as
 The Notice of Appeal was filed on A brief in complifiling the Notice of Appeal (37 CFR 41.37(a)), or any exter Notice of Appeal has been filed, any reply must be filed with AMENDMENTS 	nsion thereof (37 CFR 41.37(e)), to	avoid dismissal of the	
3. The proposed amendment(s) filed after a final rejection, be	but prior to the data of filing a brief	will not be entered be	201100
(a) ☐ They raise new issues that would require further cor (b) ☐ They raise the issue of new matter (see NOTE below (c) ☐ They are not deemed to place the application in better	nsideration and/or search (see NOT w);	E below);	
appeal; and/or	11 3	3 1 7 3	
(d) ☐ They present additional claims without canceling a c NOTE: (See 37 CFR 1.116 and 41.33(a)).	corresponding number of finally reje	cted claims.	
4. The amendments are not in compliance with 37 CFR 1.12	21. See attached Notice of Non-Cor	mpliant Amendment (F	PTOL-324).
5. Applicant's reply has overcome the following rejection(s):			
 Newly proposed or amended claim(s) would be all non-allowable claim(s). 	owable if submitted in a separate, t	imely filed amendmen	t canceling the
7. For purposes of appeal, the proposed amendment(s): a) [how the new or amended claims would be rejected is prov The status of the claim(s) is (or will be) as follows: Claim(s) allowed:		be entered and an ex	planation of
Claim(s) objected to: Claim(s) rejected: <u>9 and 12-14</u> .			
Claim(s) withdrawn from consideration:			
AFFIDAVIT OR OTHER EVIDENCE			
 The affidavit or other evidence filed after a final action, but because applicant failed to provide a showing of good and was not earlier presented. See 37 CFR 1.116(e). 			
 The affidavit or other evidence filed after the date of filing a entered because the affidavit or other evidence failed to or showing a good and sufficient reasons why it is necessary 	vercome <u>all</u> rejections under appea and was not earlier presented. Se	ıl and/or appellant fails ee 37 CFR 41.33(d)(1)	to provide a
10. ☐ The affidavit or other evidence is entered. An explanation REQUEST FOR RECONSIDERATION/OTHER	n of the status of the claims after er	itry is below or attache	ed.
 The request for reconsideration has been considered but <u>See Continuation Sheet.</u> 	does NOT place the application in	condition for allowand	ce because:
12. ☐ Note the attached Information <i>Disclosure Statement</i> (s). (13. ☐ Other:	PTO/SB/08) Paper No(s)		
/Randy Gulakowski/			
Supervisory Patent Examiner, Art Unit 1796			

Continuation of 11. does NOT place the application in condition for allowance because: The proposed amendment will be entered because it clarifies the issue raised under 112, first paragraph. Accordingly, the 112, first paragraph rejection of claims 9 and 12-14 is withdrawn.

The examiner maintains the position set forth in the Final Office Action. In paragraph 8 of the Office Action mailed on 6/24/2008, the examiner is stating that Hayashi fails to disclose the claimed wt% of the microcapsules, not that it fails to disclose any wt% of microcapsules. The examiner then directs (in paragraph 9 of the action) to [0118] of Hayashi which exemplifies about 0.17-16wt% of microcapsules. Applicant's argued that such wt% cannot be found on [0018], however, as noted, the citation is to [0118].

Applicants argue that it would not have been obvious to increase the amount of the microcapsules. However the examiner has set forth rational tending to show that an increase in the amount of microcapsules would yield beneficial results. Furthermore, it is not necessary that Liang solve the same problem as applicants. The reference recognizes size distribution as a result effective variable For both arguments MPEP § 2144.05 holds that generally, differences in concentration will not support the patentability of subject matter encompassed by the prior art unless there is evidence indicated such a concentration is critical. Wherein applicants have failed to provide evidence that the concentration is critical, the size distribution is critical, and /or that the combination of the two elements yields unexpected results.

Specifically, the evidence provided in the Declaration merely affirms that the claimed subject matter functions as it was intended to function. The evidence fails to provide proof of unexpectedly improved properties. The Office Action detailed the specific deficiencies of the declaration, which will not be repeated herein. Accordingly, in view of the foregoing the rejection has been maintained.